TAM
EIGR
Tocqueville Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-37,325
| Closed | -$8.38K | – | 557 |
|
|
2023
Q4 | $8.38K | Sell |
37,325
-13,750
| -27% | -$3.09K | ﹤0.01% | 515 |
|
|
2023
Q3 | $15.6K | Hold |
51,075
| – | – | ﹤0.01% | 509 |
|
|
2023
Q2 | $36K | Hold |
51,075
| – | – | ﹤0.01% | 531 |
|
|
2023
Q1 | $45.8K | Hold |
51,075
| – | – | ﹤0.01% | 523 |
|
|
2022
Q4 | $60.3K | Sell |
51,075
-20,500
| -29% | -$24.2K | ﹤0.01% | 568 |
|
|
2022
Q3 | $539K | Buy |
71,575
+9,000
| +14% | +$67.8K | 0.01% | 437 |
|
|
2022
Q2 | $394K | Buy |
62,575
+800
| +1% | +$5.1K | 0.01% | 535 |
|
|
2022
Q1 | $513K | Buy |
61,775
+2,700
| +5% | +$22.4K | 0.01% | 511 |
|
|
2021
Q4 | $307K | Buy |
59,075
+750
| +1% | +$3.9K | ﹤0.01% | 642 |
|
|
2021
Q3 | $390K | Buy |
58,325
+6,400
| +12% | +$42.7K | 0.01% | 585 |
|
|
2021
Q2 | $442K | Sell |
51,925
-1,000
| -2% | -$8.43K | 0.01% | 580 |
|
|
2021
Q1 | $468K | Sell |
52,925
-12,000
| -18% | -$106K | 0.01% | 564 |
|
|
2020
Q4 | $798K | Sell |
64,925
-5,250
| -7% | -$64.5K | 0.01% | 475 |
|
|
2020
Q3 | $571K | Buy |
70,175
+8,200
| +13% | +$66.6K | 0.01% | 468 |
|
|
2020
Q2 | $595K | Buy |
61,975
+4,750
| +8% | +$45.5K | 0.01% | 467 |
|
|
2020
Q1 | $389K | Buy |
57,225
+6,350
| +12% | +$43.2K | 0.01% | 493 |
|
|
2019
Q4 | $758K | Buy |
50,875
+14,700
| +41% | +$219K | 0.01% | 488 |
|
|
2019
Q3 | $371K | Buy |
36,175
+1,925
| +6% | +$19.7K | 0.01% | 617 |
|
|
2019
Q2 | $363K | Buy |
34,250
+10,500
| +44% | +$111K | ﹤0.01% | 655 |
|
|
2019
Q1 | $332K | Sell |
23,750
-2,600
| -10% | -$36.1K | ﹤0.01% | 660 |
|
|
2018
Q4 | $268K | Buy |
26,350
+9,450
| +56% | +$96.2K | ﹤0.01% | 648 |
|
|
2018
Q3 | $203K | Buy |
+16,900
| New | +$203K | ﹤0.01% | 777 |
|